204 related articles for article (PubMed ID: 2021550)
1. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Kuusela P; Haglund C; Roberts PJ
Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
[TBL] [Abstract][Full Text] [Related]
2. Tumour marker CA 125 in patients with digestive tract malignancies.
Haglund C; Kuusela P; Roberts P; Jalanko H
Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
[TBL] [Abstract][Full Text] [Related]
3. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
[TBL] [Abstract][Full Text] [Related]
5. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
Haglund C; Roberts PJ; Jalanko H; Kuusela P
Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
Jalanko H; Kuusela P; Roberts P; Sipponen P; Haglund CA; Mäkelä O
J Clin Pathol; 1984 Feb; 37(2):218-22. PubMed ID: 6198342
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum levels of CEA and CA 242 in colorectal cancer.
Carpelan-Holmström M; Haglund C; Kuusela P; Järvinen H; Roberts PJ
Br J Cancer; 1995 Apr; 71(4):868-72. PubMed ID: 7710956
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
[TBL] [Abstract][Full Text] [Related]
9. Serum sialyl-Tn antigen levels in patients with digestive cancers.
Motoo Y; Kawakami H; Watanabe H; Satomura Y; Ohta H; Okai T; Makino H; Toya D; Sawabu N
Oncology; 1991; 48(4):321-6. PubMed ID: 1891175
[TBL] [Abstract][Full Text] [Related]
10. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
11. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of cancer-associated antigen CA-195, CA 19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancer.
Kornek G; Depisch D; Temsch EM; Scheithauer W
J Cancer Res Clin Oncol; 1991; 117(5):493-6. PubMed ID: 1890143
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
15. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
[TBL] [Abstract][Full Text] [Related]
16. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
18. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
19. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
Anzai K; Kurihara M; Izumi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
[TBL] [Abstract][Full Text] [Related]
20. Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen.
Carpelan-Holmström MA; Haglund CH; Roberts PJ
Dis Colon Rectum; 1996 Jul; 39(7):799-805. PubMed ID: 8674374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
